SGLT2 Inhibitors And Aging

Edited and approved by Stephen C. Rose, PhD, MS

A diabetes medicine has become one of the more interesting side stories in aging research. The drugs are called SGLT2 inhibitors, a mouthful of a name for medicines such as empagliflozin, dapagliflozin, and canagliflozin. They were first developed to help people with type 2 diabetes lower blood sugar. More recently, doctors have learned that some of these drugs can also protect the heart and kidneys. Now researchers are asking a newer question: could they also calm some of the cellular wear-and-tear linked with aging? A 2025 review in npj Aging argues that the idea is scientifically plausible, but still early [1].

To understand the excitement, it helps to start with what SGLT2 inhibitors actually do. SGLT2 stands for sodium-glucose cotransporter 2. It is a protein in the kidney that helps pull sugar back from urine into the bloodstream. Blocking it lets the body pass extra glucose out in the urine. That is why these medicines can lower blood sugar in type 2 diabetes. MedlinePlus, a service of the National Library of Medicine, describes empagliflozin as an SGLT2 inhibitor used for type 2 diabetes and, in certain adults, to lower the risk of serious heart failure and kidney outcomes [2].

Those heart and kidney benefits are not just theoretical. In the EMPA-REG OUTCOME trial, people with type 2 diabetes and high cardiovascular risk who took empagliflozin had fewer major cardiovascular events than those taking placebo [3]. In DAPA-HF, dapagliflozin improved outcomes in people with heart failure and reduced ejection fraction, a condition in which the heart does not pump as strongly as it should [4]. In DAPA-CKD, dapagliflozin reduced the risk of worsening kidney disease or death from kidney or cardiovascular causes in people with chronic kidney disease [5]. These are established clinical findings, and they explain why this drug class has moved far beyond its original role as a glucose-lowering tool.

The aging angle is different. It is not an approved use, and it should not be treated as one. The idea comes from a field called cellular senescence. A senescent cell is a cell that has stopped dividing but has not died. In the right setting, that can be useful. Senescence helps with wound healing and may help suppress cancer by preventing damaged cells from multiplying. The problem is that senescent cells can build up over time. Many release inflammatory chemicals, enzymes, and growth signals known as the senescence-associated secretory phenotype, or SASP. Think of it as a cell that is no longer doing its normal job but keeps sending noisy distress signals to the neighborhood.

The 2025 review summarizes evidence that diabetes, high glucose, oxidative stress, inflammation, and kidney or heart disease can all overlap with senescence biology [1]. That overlap matters because SGLT2 inhibitors seem to influence several of these same pathways. They can reduce blood pressure modestly, change how the body handles fuel, affect inflammatory signaling, and reduce oxidative stress in some experimental settings. Researchers are therefore asking whether these medicines might act as senomorphic drugs. That means they might make senescent cells less harmful, especially by quieting inflammatory signals, rather than directly killing those cells.

This is where the evidence needs careful wording. The strongest human evidence for SGLT2 inhibitors is in diabetes, heart failure, and chronic kidney disease. The evidence that they are anti-aging drugs in people is preliminary and indirect. Much of the senescence work comes from cells in dishes, animal models, or measurements that are related to aging biology but are not the same thing as proving longer, healthier human life. Some mouse studies are intriguing. For example, a 2024 study reported lifespan-related effects in male UM-HET3 mice treated later in life with canagliflozin, although mice are not small humans and the result cannot be directly converted into advice for people [6]. Another study found neuroprotective effects of canagliflozin in aged genetically diverse mice, again pointing to a possible biology worth studying rather than a finished medical answer [7].

Another possible pathway is inflammation. Chronic, low-grade inflammation is common in aging and in diseases such as diabetes, heart failure, and kidney disease. Senescent cells can add to that inflammatory background through the SASP. If SGLT2 inhibitors reduce inflammatory signaling in blood vessels, heart cells, kidney cells, or immune cells, they might improve the tissue environment even when blood sugar is not the whole story. The review also discusses oxidative stress, mitochondrial function, vascular stiffness, kidney cell aging, and stem or progenitor cells as possible pieces of the puzzle [1]. These are promising leads, but they are not the same as a clinical trial showing that healthy adults should take these medicines to slow aging.

The safety side is just as important as the promise. SGLT2 inhibitors are prescription drugs, not wellness supplements. Because they make people urinate out more glucose and fluid, they can cause increased urination, thirst, dehydration, dizziness, and genital yeast infections. Serious problems are less common but can happen, including urinary infections, allergic reactions, and ketoacidosis, a dangerous buildup of acids in the blood that may occur even when blood sugar is not extremely high. MedlinePlus advises people taking empagliflozin to discuss surgery, illness, low-carbohydrate diets, dehydration, and symptoms such as nausea, vomiting, stomach pain, tiredness, or trouble breathing with a clinician because these can be warning signs [2].

That means the practical message is not, 'Ask for an SGLT2 inhibitor to live longer.' A better message is: if you already have type 2 diabetes, heart failure, or chronic kidney disease, this drug class may be worth discussing with your clinician because it has strong evidence in those conditions. If you are healthy and interested in aging, the evidence is not there yet. Researchers still need well-designed human studies that measure meaningful outcomes, not just lab markers. They also need to know who might benefit, who might be harmed, what dose would make sense, and whether benefits would remain after years of treatment.

The most balanced view is that SGLT2 inhibitors are a successful example of drug repurposing in progress. They began as diabetes drugs, became heart and kidney drugs for many patients, and are now being studied as possible tools for healthier aging biology. That is scientifically exciting. But aging is not one disease with one switch. It is a layered process involving metabolism, inflammation, blood vessels, immune function, DNA damage, cellular cleanup systems, and much more. SGLT2 inhibitors may touch several of those systems, but they are not a shortcut around the basics of medical care.

For the general public, the bottom line is simple. SGLT2 inhibitors are real medicines with real benefits for selected patients and real risks that require medical supervision. Their possible role in senescence and aging is a serious research question, not a proven anti-aging treatment. In science, that distinction matters. It lets us stay curious without getting ahead of the evidence.

References

1. Yesilyurt-Dirican ZE, Qi C, Wang YC, et al. SGLT2 inhibitors as a novel senotherapeutic approach. npj Aging. 2025;11(1):35.
2. MedlinePlus. Empagliflozin: MedlinePlus Drug Information. National Library of Medicine. Last revised July 15, 2025.
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.
4. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008.
5. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446.
6. Miller RA, Harrison DE, Cortopassi GA, et al. Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin. GeroScience. 2024;46(5):4657-4670.
7. Jayarathne HSM, Debarba LK, Jaboro JJ, Ginsburg BC, Miller RA, Sadagurski M. Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice. Aging Cell. 2022;21(7):e13653.